FDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.